Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327963 · ClinicalTrials.gov registry record · NA
Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study
A NA study, sponsored by EndoGastric Solutions.
- Terminated
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT01327963 is a NA study that was terminated before completion, run by EndoGastric Solutions. The registered enrollment target is 110 participants.
The verdict
NCT01327963, a NA study, was terminated before completion, sponsored by EndoGastric Solutions.
- TERMINATED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this retrospective, open-label, post-market study is to evaluate the safety and efficacy of Transoral Incisionless Fundoplication (TIF) performed with EsophyX (brand name) in a broad range of GastroEsophageal Reflux Disease (GERD) patients treated at high volume centers across the United States.
Interventions
- DEVICE Transoral Incisionless Fundoplication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01327963
The ClinicalTrials.gov registry entry for NCT01327963 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EndoGastric Solutions, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transoral Incisionless Fundoplication is the first listed.
NCT01327963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01327963 about?
NCT01327963 is a clinical study titled "Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study". The purpose of this retrospective, open-label, post-market study is to evaluate the safety and efficacy of Transoral Incisionless Fundoplication (TIF) performed with EsophyX (brand name) in a broad range of GastroEsophageal Reflux Disease (GERD) patients treated at high volume centers across the Uni...
What is the current status of trial NCT01327963?
This trial is currently terminated. It is a NA study. The enrollment target is 110 participants. The study started on 2010-09. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01327963?
The interventions under investigation include: Transoral Incisionless Fundoplication (DEVICE).
Who is sponsoring clinical trial NCT01327963?
This trial is sponsored by EndoGastric Solutions, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.